Piracetam
GABA-derived cyclic compound that modulates AMPA + acetylcholine receptors. The original "nootropic" — Giurgea coined the word for it in 1972.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Pyrrolidone class. Doesn't bind GABA receptors despite the structural similarity; instead increases membrane fluidity, modulates AMPA glutamate receptors, and enhances cholinergic transmission. EU prescription drug for cortical myoclonus and post-stroke aphasia; OTC supplement in much of LATAM. Choline cofactor (alpha-GPC or CDP-choline 200-500 mg) is the standard pairing — without it, headache is the most common reported side effect.
Distilled themes from named communities — Reddit threads, forums, creator commentary. Not direct quotes; not clinical evidence. Useful for calibrating expectations against what real self-experimenters report.
Cohort splits: ~half report distinct verbal fluency / mental clarity within 1-2 weeks at 4.8 g/day attack dose; the other half feel nothing or mild headache (typically choline-deficient). Pair with alpha-GPC 300 mg.
Headache is the #1 user-reported side effect — pair with choline (alpha-GPC or CDP-choline) to mitigate. Mood blunting at chronic high-dose use possible. Avoid if pregnant or anticoagulated (mild antiplatelet activity). Effect is subtle compared to stimulant nootropics — first-dose users often report "nothing happened."
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Not FDA-approved in US — sold as research/dietary supplement under DSHEA gray zone. EU prescription drug (Nootropil, UCB Pharma).